Finally, whereas EGFR-TKIs show a poor efficacy for NSCLC positive for EGFR mutations in association with TP53 mutations14,15, whether TP53-GOF mutations confer an inferior efficacy for osimertinib in comparison with non-GOF mutations is unclear. This evidence concerns the gene TP53 and non-small cell lung carcinoma.